GH1 and obesity due to melanocortin 4 receptor deficiency: The prevalence of obesity was lower in the ‘on GH therapy’ group compared to the other two groups (51.4% in the ‘on GH therapy’ group versus 71.1% in the ‘ever on GH therapy’ group and 76% in the ‘never on GH therapy’ group) (Supplementary Table S4) (Figure 1G).